StreetInsider.com News Articles

Form 4 Arcutis Biotherapeutics, For: Aug 20 Filed by: Curran Terrie

Mon, 24 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260824/26968360.html

Form 4 Arcutis Biotherapeutics, For: Aug 20 Filed by: Curran Terrie

Mon, 24 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260824/26968360.html

Form 4 Arcutis Biotherapeutics, For: Aug 19 Filed by: Burnett Patrick

Fri, 21 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260821/26961434.html

Form 4 Arcutis Biotherapeutics, For: Aug 19 Filed by: Burnett Patrick

Fri, 21 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260821/26961434.html

Form 144 Arcutis Biotherapeutics, Filed by: Curran Terrie

Thu, 20 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260820/26956848.html

Form 144 Arcutis Biotherapeutics, Filed by: Curran Terrie

Thu, 20 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260820/26956848.html

Form 4 Arcutis Biotherapeutics, For: Aug 17 Filed by: Welgus Howard G.

Wed, 19 Aug 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260819/26950898.html

Form 4 Arcutis Biotherapeutics, For: Aug 17 Filed by: Welgus Howard G.

Wed, 19 Aug 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260819/26950898.html

Form 144 Arcutis Biotherapeutics, Filed by: Burnett Patrick

Wed, 19 Aug 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260819/26950427.html

Form 144 Arcutis Biotherapeutics, Filed by: Burnett Patrick

Wed, 19 Aug 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260819/26950427.html

Form 144 Arcutis Biotherapeutics, Filed by: Welgus Howard G.

Mon, 17 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260817/26938316.html

Form 144 Arcutis Biotherapeutics, Filed by: Welgus Howard G.

Mon, 17 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260817/26938316.html

Form SCHEDULE 13G Arcutis Biotherapeutics, Filed by: Polar Capital Holdings Plc

Fri, 14 Aug 2026 06:21:00 -0400

si-local-file:///var/storage/secattach/20260814/26924193.html

Form SCHEDULE 13G Arcutis Biotherapeutics, Filed by: Polar Capital Holdings Plc

Fri, 14 Aug 2026 06:21:00 -0400

si-local-file:///var/storage/secattach/20260814/26924193.html

Form 4 Arcutis Biotherapeutics, For: Aug 11 Filed by: Burnett Patrick

Thu, 13 Aug 2026 20:07:00 -0400

si-local-file:///var/storage/secattach/20260813/26923181.html

Form 4 Arcutis Biotherapeutics, For: Aug 11 Filed by: Burnett Patrick

Thu, 13 Aug 2026 20:07:00 -0400

si-local-file:///var/storage/secattach/20260813/26923181.html

Form 144 Arcutis Biotherapeutics, Filed by: Burnett Patrick

Tue, 11 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260811/26907065.html

Form 144 Arcutis Biotherapeutics, Filed by: Burnett Patrick

Tue, 11 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260811/26907065.html

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 07 Aug 2026 16:00:00 -0400

WESTLAKE VILLAGE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 143,500 restricted stock units (RSUs) of Arcutis’ common stock as well as options to purchase an aggregate of 37,000 shares of Arcutis’ common stock to 24 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of August 3, 2026, as

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 07 Aug 2026 16:00:00 -0400

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 07 Aug 2026 16:00:00 -0400

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 07 Aug 2026 16:00:00 -0400

Form SCHEDULE 13G Arcutis Biotherapeutics, Filed by: STATE STREET CORP

Fri, 07 Aug 2026 08:57:00 -0400

si-local-file:///var/storage/secattach/20260807/26888221.html

Form SCHEDULE 13G Arcutis Biotherapeutics, Filed by: STATE STREET CORP

Fri, 07 Aug 2026 08:57:00 -0400

si-local-file:///var/storage/secattach/20260807/26888221.html

Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $38 at Guggenheim

Thu, 06 Aug 2026 07:28:40 -0400

(Updated - August 6, 2026 7:28 AM EDT)

Guggenheim analyst Seamus Fernandez raised the price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) to $38.00 (from $35.00) while maintaining a Buy rating.

The analyst commented: "Strong 2Q26 Zoryve sales of $129.9M handily beat both our/consensus estimates of $117.5M/$118.5M; total revenue increased +59% y/y and +23% q/q, driven by increasing demand across products as well as improved GTN pricing. ARQT anticipates continued demand through the duration of this year driving portfolio growth in 2H26, but noted any further improvements will be incremental at best given the already strong GTN. Of note, the company expects